After being bed-ridden with a severe case of pneumonia for four months, I had resolved to living a healthy lifestyle; as possible. I cut out almost all sugar and grains, focusing my diet on vegetables and protein, and started to exercise regularly for the first time in my adult life. I lost 50 pounds and was feeling great. Then, in my late 20s, I became more fatigued than I had felt since having mono during college. I was prescribed an antibiotic, and everything got worse. The fatigue became more severe, to the point that all I was able to do was lay down, sleep, and go to the bathroom, and I spent a great deal of time doing the latter.
After following up with my doctor and referral to a specialist, a colonoscopy confirmed that I had Irritable Bowel Disease (IBD), or, for me personally, a “moderate” case of ulcerative colitis (UC). Most of the next two years were spent in and out of flare-ups, experimenting with dietary restrictions, and constantly trying new medications and adjusting doses. During this time, when I was able to function, it was like walking around with a time-bomb in my gut. It might go off at any time, and if it did, I would have one minute (at the most) to find a bathroom.
IBD can affect incredibly diverse areas of life. For me, the first symptom I notice when the condition is worsening, before there are any impacts on bathroom usage, is depression. This is my “canary in the coal mine”. Symptoms also become worse with stress, which means symptoms can become more severe at very inopportune times. When you are running late, you are more likely to need to use the bathroom. It can be difficult to go anywhere that a bathroom will not be convenient, such as conferences and concerts, going on a long drive or sitting in traffic, or even taking a walk around your own neighbourhood, because knowing that a bathroom will not be available adds stress to the situation.
Socially, there are also constant reminders as so much of culture revolves around food. As one of the main ways of controlling IBD is dietary restriction, you always have to be on guard with food that you have not prepared for yourself. This can be insidiously socially isolating. For me, I have found my primary restrictions to be wheat gluten, grains more broadly, sugar, alcohol, and coffee or tea. Intolerance of these ingredients means no pizza with friends, no cake at birthdays or weddings, no fried foods, no dessert when you want an indulgence, and having difficulties going to a happy-hour after work, or even meeting friends for coffee on the weekend. When you do go out to a restaurant, seeing bread on the table and someone ordering an appetizer, often fried, means you are likely to have to wait for an hour or more while everyone else eats before anything you can eat will be on the table. It also means being the difficult customer who questions waiters about how food is prepared, down to whether French fries are coated in flour to make them crispier, whether meats have been marinated with soy sauce, and even whether balsamic vinegar is used in preparing the food.
This experience with IBD/UC has given me an appreciation for the many ways in which a condition can affect the life of a patient, and I carry this into any project that I work on. Getting a full picture of the patient experience extends well beyond the physical symptoms they may experience. We need to consider how the patient feels about the condition, what they need to do to control the condition, and the impacts of trying to treat the condition. Even beyond this, what may have worked in the past may change in the future, so symptoms, treatments, and impacts may change over time. Having this perspective has helped on studies of not only digestive issues, but on every project I have worked on.
Ryan Murphy
Outcomes Researcher
ICON Global Health Economics, Outcomes Research & Epidemiology (GHEORE)
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel